vzphotos/iStock Editorial via Getty Images Micron Technology ( MU ) heads into its earnings report with broadly bullish sentiment from both quantitative models and Wall Street. Seeking Alpha’s Quant Rating assigns Micron a Strong Buy , backed by robust growth, strong profitability, solid momentum, and positive earnings revisions—pointing to continued strength in the memory cycle, even as valuation...
vzphotos/iStock Editorial via Getty Images Micron Technology ( MU ) heads into its earnings report with broadly bullish sentiment from both quantitative models and Wall Street. Seeking Alpha’s Quant Rating assigns Micron a Strong Buy , backed by robust growth, strong profitability, solid momentum, and positive earnings revisions—pointing to continued strength in the memory cycle, even as valuation appears somewhat stretched. Quant Rating History (Seeking Alpha) Wall Street analysts are also constructive, maintaining a Buy rating. However, the average price target of $432.49 implies about 6.3% downside, indicating that much of the near-term upside may already be priced in following the stock’s sharp run. Shares have surged nearly 62% year-to-date and an impressive 353.8% over the past year, underscoring the strength of the rally. Overall, the market remains confident in Micron’s fundamentals but is growing more cautious on valuation after the outsized gains. With expectations elevated, the company’s earnings and forward guidance will be key in determining whether the rally can extend further. Michael Kramer, Investing Group Leader for Mott Capital Management, suggests MU stock may plunge following upcoming fiscal Q2 earnings, even if it reports stellar results. “With implied volatility near 120% and heavy call-side positioning, the setup requires results and guidance to exceed even the most bullish expectations just to push the stock higher.” The open interest put/call ratio for Micron Technology ( MU ) stands at 1.32, signaling a bearish bias, as a ratio above 1 typically reflects greater demand for puts over calls, while a ratio below 1 indicates bullish sentiment. Options pricing implies that Micron’s stock could move about 7.5% in either direction by the end of the week. Historically, the stock has shown mixed reactions to earnings—falling 8% after 2Q25 results, remaining nearly flat post 3Q25, declining 2.8% following 4Q25, and rising 10% after 1Q26. Wall Street...
Weibo press release ( WB ): Q4 Non-GAAP EPS of $0.25 misses by $0.07 . Revenue of $473.3M (+3.6% Y/Y) beats by $29.02M . Monthly active users ("MAUs") were 567 million in December 2025. Average daily active users ("DAUs") were 252 million in December 2025. Advertising and marketing revenues were US$403.8 million, an increase of 5% year-over-year or an increase of 2% year-over-year on a constant cu...
Weibo press release ( WB ): Q4 Non-GAAP EPS of $0.25 misses by $0.07 . Revenue of $473.3M (+3.6% Y/Y) beats by $29.02M . Monthly active users ("MAUs") were 567 million in December 2025. Average daily active users ("DAUs") were 252 million in December 2025. Advertising and marketing revenues were US$403.8 million, an increase of 5% year-over-year or an increase of 2% year-over-year on a constant currency basis. Value-added services ("VAS") revenues were US$69.5 million, a decrease of 2% year-over-year or a decrease of 4% year-over-year on a constant currency basis. More on Weibo Weibo Corporation: Has Enough Going For It To Take It Higher Seeking Alpha’s Quant Rating on Weibo Historical earnings data for Weibo Dividend scorecard for Weibo Financial information for Weibo
Evgeny Gromov/iStock via Getty Images By Dina Ting, CFA, Head of Global Index Portfolio Management, Franklin Templeton ETFs China’s underappreciated equity market and energy resilience amid current geopolitical tensions warrant consideration, according to Franklin Templeton ETFs’ Dina Ting. In this article, she discusses the different factors that underpin her views. An underappreciated theme shap...
Evgeny Gromov/iStock via Getty Images By Dina Ting, CFA, Head of Global Index Portfolio Management, Franklin Templeton ETFs China’s underappreciated equity market and energy resilience amid current geopolitical tensions warrant consideration, according to Franklin Templeton ETFs’ Dina Ting. In this article, she discusses the different factors that underpin her views. An underappreciated theme shaping this year’s China story is energy resilience amid rising geopolitical risk. As conflict around Iran and the Strait of Hormuz roils oil markets, Beijing’s multi-layered energy security strategy is drawing attention for its potential to cushion vulnerability through stockpiling, diversification, and strategic infrastructure. For more than two decades, China has expanded its strategic petroleum reserves and built storage capacity as part of a hedge against supply disruption. While the country remains the world’s largest net crude importer and is exposed to sustained price spikes, its diversified sourcing and overland corridors reduce reliance on any single maritime chokepoint. These measures do not eliminate oil risk, but they may help contain spillover into China’s broader economy. Compared with several major energy-importing economies, China is in a somewhat less precarious position. Japan relies on imports for roughly 85% to 90% of its primary energy, and the European Union imports more than half of its energy needs. India, meanwhile, imports the vast majority of its crude oil. 1 While countries such as Japan also maintain sizable strategic petroleum reserves, reserves alone do not change underlying import dependence or energy mix. China remains heavily reliant on imported oil but generates most of its electricity from abundant domestic coal and has spent years building and securing diversified supply routes - moderating broader energy vulnerability even if it is not fully insulated. That relative insulation has been visible in markets. Within the first 11 trading days ...
蒙哥马利峰会的开幕活动现场。 作者：Julia Hornstein 2026 年，把数百位风险投资家和有限合伙人聚在一起，绝大多数人都已实实在在押注 AI，这一点毫不意外。因此，上周在加州圣莫尼卡举行的 March Capital 年度蒙哥马利峰会上，投资者们眼中 AI 热潮的 薄弱环节 格外值得关注。 以马德罗纳风险投资公司（Madrona）董事总经理马特・麦基尔韦恩为例。他在一场圆桌讨论中表示...
蒙哥马利峰会的开幕活动现场。 作者：Julia Hornstein 2026 年，把数百位风险投资家和有限合伙人聚在一起，绝大多数人都已实实在在押注 AI，这一点毫不意外。因此，上周在加州圣莫尼卡举行的 March Capital 年度蒙哥马利峰会上，投资者们眼中 AI 热潮的 薄弱环节 格外值得关注。 以马德罗纳风险投资公司（Madrona）董事总经理马特・麦基尔韦恩为例。他在一场圆桌讨论中表示，这家总部位于西雅图的风投机构发现，过去二十年间，AI 驱动的应用类企业增速快于其他类型公司。他看好 AI 应用，尤其是那些整合多种不同模型并进行微调、打造出独特产品的应用 —— 但他仍提出疑问： “它们能否保持长期竞争力？” 这种务实态度在过去三年里一直若隐若现。投资者担心，建立在 AI 基础大模型之上的 AI 软件，很快会被 OpenAI、Anthropic、 谷歌 等巨头的竞品边缘化。AI 文案写作应用 Jasper 就是早期典型案例：它此前每月收费 80 美元，可 OpenAI 推出 ChatGPT 后，免费就能撰写信件和商业方案，Jasper 随即陷入困境。 尽管如此，在随后几年里，风投们仍投资了数十个 AI 应用项目，其中一些项目估值翻倍甚至翻四倍，迅速完成融资。 部分投资者认为，某些 AI 应用可以通过 专用数据 对 AI 进行定制化改造，以此抵御大模型厂商的冲击，例如法律类应用使用的案例卷宗、Runway 使用的电影片库等。Madrona 去年新募集近 8 亿美元资金，部分就是用于投资这类 “应用型 AI 应用”。此后，该机构投资了 Vercept 等 AI 应用，这款 AI 桌面助手已于上月被 Anthropic 收购。 举办本次峰会的成长期风投机构 March Capital 联合创始人、管理合伙人苏曼特・曼达尔也对 AI 应用的前景提出质疑，因为大模型厂商正在推出自研垂直产品，比如 Anthropic 的 Claude Code，以及可审核合同、起草文件的法律工具 Cowork。 他在采访中表示： “模型的边界在哪里，应用又从何处开始？” 他还补充道，投资者现在应该思考，究竟是大模型开发商还是 AI 应用能带来最丰厚的回报。March Capital 已投资法律科技初创公司 Luminance 等 AI 应用项目。 AI 企业实现高速增长的原因之一，是...
Love & Fury: how poster artists responded to the Aids crisis – in pictures A new exhibition explores how graphic design helped define New York City’s response to Aids from the late 1970s to the 2000s. Grassroots groups such as Gay Men’s Health Crisis and Act Up created posters to promote safe sex and healthcare, as well as calling out the Reagan administration for inaction in the face of the crisi...
Love & Fury: how poster artists responded to the Aids crisis – in pictures A new exhibition explores how graphic design helped define New York City’s response to Aids from the late 1970s to the 2000s. Grassroots groups such as Gay Men’s Health Crisis and Act Up created posters to promote safe sex and healthcare, as well as calling out the Reagan administration for inaction in the face of the crisis. Love & Fury: New York’s Fight Against AIDS is on display until 6 September.
JHVEPhoto/iStock Editorial via Getty Images Investment Thesis The share price of Thermo Fisher ( TMO ) had a difficult start to 2026 and has declined by approx. 20% since the beginning of the year. In my view, this creates an attractive entry point considering the company's quality and the broad platform. Thermo Fisher is one of the most important infrastructure providers in the global life scienc...
JHVEPhoto/iStock Editorial via Getty Images Investment Thesis The share price of Thermo Fisher ( TMO ) had a difficult start to 2026 and has declined by approx. 20% since the beginning of the year. In my view, this creates an attractive entry point considering the company's quality and the broad platform. Thermo Fisher is one of the most important infrastructure providers in the global life sciences industry. It covers a large part of the value chain, from scientific research to drug manufacturing and clinical diagnostics. Although the life science tools sector is currently undergoing a slowdown following the COVID-19 investment binge and weaker biotech funding, I view the long-term drivers of healthcare innovation as remaining intact. At the current valuation level, I view Thermo Fisher as an attractive opportunity for long-term-oriented investors. Company Overview What Thermo Fisher Does Thermo Fisher is one of the world's largest suppliers of laboratory equipment, life science reagents, and research services. The company also provides tools and technologies to study biological systems, develop medicines, and diagnose diseases. So, Thermo Fisher builds many of the tools that researchers need to do experiments and manufacture modern medicines. The main customers are biopharma companies and hospitals, but also government laboratories and universities. A key feature of Thermo's business model is the combination of scientific instruments (which are generally capex for customers) and recurring consumables (which are generally opex). Once a laboratory installs Thermo Fisher equipment, it typically continues to purchase consumables and services from the company for many years. Products and Offerings Business Segments (Thermo Fisher 10K) Thermo Fisher is organized in four business segments . The Life Sciences Solutions focuses on reagents, kits, and instruments used in biological research and diagnostics. A large part of this business is consumables, which therefore creat...
Boring is beautiful. That adage is especially true during turbulent times. If you haven't noticed, the current market and world conditions are quite tumultuous. In a highly volatile market, boring dividend stocks can be the ultimate defensive play. Bristol Myers Squibb (BMY 0.17%) is such a stock. It has delivered a double-digit year-to-date gain while the S&P 500 (^GSPC +0.25%) has fallen. I'd ha...
Boring is beautiful. That adage is especially true during turbulent times. If you haven't noticed, the current market and world conditions are quite tumultuous. In a highly volatile market, boring dividend stocks can be the ultimate defensive play. Bristol Myers Squibb (BMY 0.17%) is such a stock. It has delivered a double-digit year-to-date gain while the S&P 500 (^GSPC +0.25%) has fallen. I'd happily hold Bristol Myers Squibb through any crash. Expand NYSE : BMY Bristol Myers Squibb Today's Change ( -0.17 %) $ -0.10 Current Price $ 59.61 Key Data Points Market Cap $122B Day's Range $ 59.59 - $ 60.80 52wk Range $ 42.52 - $ 62.89 Volume 450K Avg Vol 13M Gross Margin 65.89 % Dividend Yield 4.17 % What about Bristol Myers Squibb's patent cliff? Let's address what's probably the biggest objection about Bristol Myers Squibb -- its patent cliff. The company's two top-selling drugs, blood thinner Eliquis and cancer immunotherapy Opdivo, both lose patent exclusivity in 2028. Blood cancer drug Revlimid already faces generic competition. However, Bristol Myers Squibb hasn't backed away from its challenges. The company's revenue continues to shift to its growth portfolio, which consists primarily of newer drugs. In 2025, this growth portfolio accounted for roughly 55% of total revenue, up from around 47% the previous year. Bristol Myers Squibb also boasts a promising pipeline. The drugmaker expects to report results from pivotal clinical studies for 28 programs by the end of 2028. Half of these programs are new therapies, while the other half are potential new indications for already approved drugs. The company has also completed several key acquisitions to bolster its growth prospects. For example, Bristol Myers Squibb purchased Orbital Therapeutics last year to gain access to its next-generation CAR-T therapy, OTX-201. In 2024, BMS acquired Karuna Therapeutics, adding the potential blockbuster neuroscience drug KarXT to its pipeline. A stock that income investors should lov...
Key Points Bristol Myers Squibb's stock has performed well so far this year, while the broader market has stumbled. Although the drugmaker faces a patent cliff, its growth portfolio makes up over half of total revenue. Bristol Myers Squibb's dividend is a big plus. 10 stocks we like better than Bristol Myers Squibb › Boring is beautiful. That adage is especially true during turbulent times. If you...
Key Points Bristol Myers Squibb's stock has performed well so far this year, while the broader market has stumbled. Although the drugmaker faces a patent cliff, its growth portfolio makes up over half of total revenue. Bristol Myers Squibb's dividend is a big plus. 10 stocks we like better than Bristol Myers Squibb › Boring is beautiful. That adage is especially true during turbulent times. If you haven't noticed, the current market and world conditions are quite tumultuous. In a highly volatile market, boring dividend stocks can be the ultimate defensive play. Bristol Myers Squibb (NYSE: BMY) is such a stock. It has delivered a double-digit year-to-date gain while the S&P 500 (SNPINDEX: ^GSPC) has fallen. I'd happily hold Bristol Myers Squibb through any crash. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » What about Bristol Myers Squibb's patent cliff? Let's address what's probably the biggest objection about Bristol Myers Squibb -- its patent cliff. The company's two top-selling drugs, blood thinner Eliquis and cancer immunotherapy Opdivo, both lose patent exclusivity in 2028. Blood cancer drug Revlimid already faces generic competition. However, Bristol Myers Squibb hasn't backed away from its challenges. The company's revenue continues to shift to its growth portfolio, which consists primarily of newer drugs. In 2025, this growth portfolio accounted for roughly 55% of total revenue, up from around 47% the previous year. Bristol Myers Squibb also boasts a promising pipeline. The drugmaker expects to report results from pivotal clinical studies for 28 programs by the end of 2028. Half of these programs are new therapies, while the other half are potential new indications for already approved drugs. The company has also completed several key acquisitions to bolster its growth prospects. For ex...
Bet_Noire/iStock via Getty Images Matador Resources Analysis Data by YCharts My coverage universe is precious metals, and that's where I've spent 50-75% of my time analyzing stocks. But every so often I come across a name outside that world that checks so many boxes I can't ignore it. Matador Resources ( MTDR ) is one of those names. What caught my attention initially was the insider buying. I'm a...
Bet_Noire/iStock via Getty Images Matador Resources Analysis Data by YCharts My coverage universe is precious metals, and that's where I've spent 50-75% of my time analyzing stocks. But every so often I come across a name outside that world that checks so many boxes I can't ignore it. Matador Resources ( MTDR ) is one of those names. What caught my attention initially was the insider buying. I'm a big fan of insider buying as it generally means that insiders are bullish on the stock, think it's a good value, and believe it will rise. I spend a lot of time tracking SEDI filings and Form 4s in the mining space because following insiders' leads into a stock has proven to be a great addition to my overall analysis of an equity. When I saw that Matador's management has made 78 open-market purchases with zero sales since 2021, I had to dig deeper. That's not just bullish, instead, that's conviction I almost never see. The more I dug into this name, the more I liked. This is a Delaware Basin operator with four decades of history, industry-leading profit margins, a balance sheet that's been cleaned up, and a midstream business generating nearly $300 million in annual EBITDA that management is actively exploring strategic alternatives for. The whole thing trades at an EV/EBITDA below 4.5x, which is far too cheap, as I argue below. The Numbers: Record Year, Cheap Stock Matador's full-year 2025 was strong across the board. Oil and gas revenue totaled $3.24 billion. Net income attributable to shareholders was $759.2 million, or $6.09 per diluted share. Q4 production averaged 211,290 BOE per day, including 121,363 barrels of oil per day, both records. Proved reserves grew 9% to 667 million BOE with a PV-10 of $8.24 billion. The cost discipline is what really stands out to me thouggh. Drilling and completion costs ran approximately $825 per completed lateral foot and lease operating expenses came in at $5.56 per BOE. And the company managed to cut its combined 2026 capex by 11% t...
Alphabet (GOOGL +1.75%) (GOOG +1.61%) recently disclosed CEO Sundar Pichai's pay package, offering some interesting insights into the direction the company is headed. Pichai receives a base salary of $2 million as CEO, but if certain goals are met, his pay over the next few years could jump to $692 million. And one of the most intriguing goals, potentially contributing up to $130 million of his pa...
Alphabet (GOOGL +1.75%) (GOOG +1.61%) recently disclosed CEO Sundar Pichai's pay package, offering some interesting insights into the direction the company is headed. Pichai receives a base salary of $2 million as CEO, but if certain goals are met, his pay over the next few years could jump to $692 million. And one of the most intriguing goals, potentially contributing up to $130 million of his pay, is tied directly to the growth of Alphabet's robotaxi business, Waymo. Waymo is driving a large portion of Pichai's pay Alphabet laid out some of the details of Pichai's pay in a recent SEC filing, saying that if Waymo's per-unit value over three years increases, then he may be eligible for the equity award. That essentially means the company's board will track Waymo's value over the next few years, and Pichai's pay could increase significantly based on the company's growth. What the filing doesn't tell us is how Alphabet's board will measure this. For example, it doesn't say anything about the number of rides customers take or Waymo's revenue goals. But with such a potentially large amount of Pichai's salary tied to Waymo, it's an indication that Alphabet is getting even more serious about the growth of its self-driving car over the next few years. Accelerating into a $2 trillion market Waymo recently closed a new $16 billion funding round, which raised the company's valuation to a stunning $116 billion. And with such massive potential for self-driving cars over the coming years, it's not surprising to see Alphabet tying a large chunk of its CEO's pay to its success. Some estimates put the size of the autonomous vehicle market at $2.2 trillion by 2030. That's a massive market, and it's why companies including Uber, Tesla, Amazon, and Lucid are trying to take a slice of it. Expand NASDAQ : GOOGL Alphabet Today's Change ( 1.75 %) $ 5.35 Current Price $ 310.91 Key Data Points Market Cap $3.8T Day's Range $ 305.52 - $ 311.40 52wk Range $ 140.53 - $ 349.00 Volume 858K Avg Vo...
Jessica Simpson has reportedly decided to hold on to the $17.9 million Los Angeles mansion she bought with her estranged spouse, Eric Johnson, who is understood to have moved out of the property .
Jessica Simpson has reportedly decided to hold on to the $17.9 million Los Angeles mansion she bought with her estranged spouse, Eric Johnson, who is understood to have moved out of the property .
Key Points Up to $130 million of Pichai's pay package over the next several years is tied to Waymo. Waymo recently completed a $16 billion investment round and is expanding into new cities this year. The autonomous vehicle market could be worth more than $2 trillion by 2030. 10 stocks we like better than Alphabet › Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) recently disclosed CEO Sundar Pichai's pay ...
Key Points Up to $130 million of Pichai's pay package over the next several years is tied to Waymo. Waymo recently completed a $16 billion investment round and is expanding into new cities this year. The autonomous vehicle market could be worth more than $2 trillion by 2030. 10 stocks we like better than Alphabet › Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) recently disclosed CEO Sundar Pichai's pay package, offering some interesting insights into the direction the company is headed. Pichai receives a base salary of $2 million as CEO, but if certain goals are met, his pay over the next few years could jump to $692 million. And one of the most intriguing goals, potentially contributing up to $130 million of his pay, is tied directly to the growth of Alphabet's robotaxi business, Waymo. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Waymo is driving a large portion of Pichai's pay Alphabet laid out some of the details of Pichai's pay in a recent SEC filing, saying that if Waymo's per-unit value over three years increases, then he may be eligible for the equity award. That essentially means the company's board will track Waymo's value over the next few years, and Pichai's pay could increase significantly based on the company's growth. What the filing doesn't tell us is how Alphabet's board will measure this. For example, it doesn't say anything about the number of rides customers take or Waymo's revenue goals. But with such a potentially large amount of Pichai's salary tied to Waymo, it's an indication that Alphabet is getting even more serious about the growth of its self-driving car over the next few years. Accelerating into a $2 trillion market Waymo recently closed a new $16 billion funding round, which raised the company's valuation to a stunning $116 billion. And with such massive potential for s...